Ushering in the Golden Era of Alzheimer Drug Development?

Video

What effect will aducanumab have on Alzheimer disease treatment?

RJ Tesi, MD, discusses the recent aducanumab FDA approval and the implications it will have on the treatment of Alzheimer disease.

Dr Tesi is CEO and Chief Medical Officer of INmuneBio.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
Related Content
This alters the course of developer Eisai's regulatory submission plans for lecanemab in the treatment of early Alzheimer disease.

FDA: Specific Fast Track Designation for Subcutaneous Formulation of Leqembi for Alzheimer Disease Needed for Rolling Review

April 3rd 2024
Article
What Will the Future of Alzheimer Disease Treatment Look Like?

What Will the Future of Alzheimer Disease Treatment Look Like?

July 23rd 2021
Podcast
The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From the Pages of Psychiatric Times: March 2024

March 30th 2024
Article
Site Logo

The Relevance of New Alzheimer Guidelines for Clinical Practice

August 16th 2012
Podcast
FDA

Donanemab Delay: FDA Calls for Last-Minute Meeting to Discuss Safety and Efficacy

March 8th 2024
Article
Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease

February 20th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.